Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 17/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 2/20 | 0.44 |
| ▸ | CLK3 | P49761 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20618201 | 0.84 | GSK3B (0.40) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL24985762 | 0.77 | CCNE1 (0.38) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL21755111 | 0.77 | RIPK1 (0.53) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL24987967 | 0.75 | CCNE1 (0.38) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31704117 | 0.72 | CCNB2 (0.65) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL14838870 | 0.72 | CCNB2 (0.65) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL20622229 | 0.71 | GSK3B (0.36) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL23389649 | 0.71 | RIPK1 (0.52) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL29796712 | 0.71 | RIPK1 (0.52) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL3672721 | 0.71 | RIPK1 (0.54) | RIPK1CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | RIPK1 2027/4885CCNB2 2238/4885CDK1 1453/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | RIPK1 2027/4885CCNB2 2238/4885CDK1 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.